



HAL
open science

Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies

Simon G Thompson, Stephen Kaptoge, I White, Angela M Wood, Philip Perry, J Danesh

► To cite this version:

Simon G Thompson, Stephen Kaptoge, I White, Angela M Wood, Philip Perry, et al.. Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. *International Journal of Epidemiology*, 2010, 10.1093/ije/DYQ063 . hal-00589969

HAL Id: hal-00589969

<https://hal.science/hal-00589969>

Submitted on 3 May 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Statistical methods for the time-to-event analysis of
individual participant data from multiple epidemiological
studies**

Journal:	<i>International Journal of Epidemiology</i>
Manuscript ID:	IJE-2009-07-0622.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	22-Feb-2010
Complete List of Authors:	Thompson, Simon; MRC Biostatistics Unit Kaptoge, Stephen; University of Cambridge, Department of Public Health & Primary Care White, I; MRC Biostatistics Unit Wood, Angela; University of Cambridge, Department of Public Health & Primary Care Perry, Philip; University of Cambridge, Department of Public Health & Primary Care Danesh, J; University of Cambridge, Department of Public Health & Primary Care
Key Words:	Meta-analysis, Epidemiological studies, Individual participant data, Statistical methods, Survival analysis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies

The Emerging Risk Factors Collaboration*

Revised paper submitted to *International Journal of Epidemiology*, February 2010

*Authors listed in the Appendix

Author for correspondence:

Professor S G Thompson

MRC Biostatistics Unit

Institute of Public Health

Robinson Way

Cambridge CB2 0SR, UK

Tel: +44 1223 330366

Fax: +44 1223 330388

Email: simon.thompson@mrc-bsu.cam.ac.uk

Word counts: Abstract 231, Main text 4383

Keywords / MeSH headings: Meta-analysis, epidemiological studies, individual participant data, statistical methods, survival analysis

ABSTRACT

Background: Meta-analysis of individual participant time-to-event data from multiple prospective epidemiological studies enables detailed investigation of exposure-risk relationships, but involves a number of analytical challenges.

Methods: This paper describes statistical approaches adopted in the Emerging Risk Factors Collaboration, in which primary data from over 1 million participants in over 100 prospective studies have been collated to enable detailed analyses of a variety of risk markers in relation to incident cardiovascular disease outcomes.

Results: Analyses have been principally based on Cox proportional hazards regression models stratified by sex, undertaken in each study separately. Estimates of exposure-risk relationships, initially unadjusted and then adjusted for several confounders, have been combined over studies using meta-analysis. Methods for assessing the shape of exposure-risk associations and the proportional hazards assumption have been developed. Estimates of interactions have also been combined using meta-analysis, keeping separate within- and between-study information.

Regression dilution bias caused by measurement error and within-person variation in exposures and confounders has been addressed through the analysis of repeat measurements to estimate corrected regression coefficients. These methods are exemplified by analysis of plasma fibrinogen and risk of coronary heart disease, and Stata code is made available.

Conclusion: Increasing numbers of meta-analyses of individual participant data from observational data are being conducted to enhance the statistical power and detail of epidemiological studies. The statistical methods developed here can be used to address the needs of such analyses.

KEY MESSAGES

Summarising exposure-risk relationships based on individual time-to-event data from multiple studies enhances the detail and power of epidemiological analyses

A 2-step meta-analysis method is proposed to combine study-specific associations estimated using Cox regression

These methods allow investigation of the appropriate exposure scale, adjustment for confounders, and checking the proportional hazards assumption

Within-study and between-study information for interactions need to be distinguished

More technically demanding issues include adjustment for measurement error and within-person variation, and handling confounders which are not measured in all studies

INTRODUCTION

Combining information across several studies using meta-analysis can enhance precision for quantitative summaries of evidence.¹ Re-analysis of individual participant data (IPD) from multiple epidemiological studies has several advantages compared to meta-analysis of aggregated published data, including: harmonisation of definitions for risk markers as well as disease outcomes; ability to update follow-up information; consistent approaches to adjustment for confounding; characterisation of the shape of exposure-risk relationships; greater ability to correct for regression dilution bias; and determination of how exposure-risk relationships depend on age, sex and other potential effect modifiers.²⁻⁴ This paper describes and illustrates statistical methods that are being used in the Emerging Risk Factors Collaboration (ERFC), an analysis of individual records from over 1.2 million participants in 116 prospective studies in predominantly Western populations of major cardiovascular disease outcomes.⁵⁻⁸ The ERFC includes mostly prospective cohort studies (a few based in randomised trials), as well as some nested case-control and case-cohort studies. For each participant in the ERFC, the coordinating centre has collated, verified and harmonised individual records on baseline risk markers, confounders, other characteristics, major cardiovascular morbidity and cause-specific mortality.⁵ Available repeat survey data, which provide serial measurements, have also been collected to help address measurement error and within-person variability.^{3,9}

As the ERFC subsumes the Fibrinogen Studies Collaboration,¹⁰ we have illustrated the statistical methods used in the ERFC by analysis of plasma fibrinogen concentration and the risk of coronary heart disease (CHD) in the Fibrinogen Studies Collaboration dataset involving individual data on 154,211 participants from 31 prospective studies. CHD is defined as first non-fatal myocardial infarction or coronary death in those without known cardiovascular disease at the initial examination.¹⁰ A total of 7118 CHD events occurred during an average of 9 years of follow-up. Across the 31 studies, the number of CHD events ranged from 17 to 1474 and follow-up from 4 to 33 years; the crude mean fibrinogen was 3.02g/L (pooled within-study SD 0.65g/L).

METHODS AND ILLUSTRATIVE ANALYSES

Principal meta-analysis methods

This exposition initially assumes that all data derive from prospective cohorts; other designs are addressed towards the end of the paper. The main analyses are based on Cox proportional hazards (PH) models,¹¹ estimated for each study separately. The PH models are stratified by sex and, if applicable, randomised group. So separately for each study $s=1 \dots S$, with strata $k=1 \dots K_s$ (for most studies $K_s=2$ just for the two sexes) and individuals $i=1 \dots n_s$ with exposure of interest E_{si} and other covariates \mathbf{X}_{si} , the hazard at time t after baseline is modelled as:

$$\log(h_{ski}(t | E_{si}, \mathbf{X}_{si})) = \log h_{0sk}(t) + \beta_s E_{si} + \gamma_s \mathbf{X}_{si} \quad (1)$$

The evolution of risk over time is thus modelled independently for each stratum in each study, as represented by the non-parametric baseline hazards $h_{0sk}(t)$. The β_s are the parameters of interest, being the log hazard ratios (HRs) per unit increase in the exposure in study s , adjusted for the confounding effects of the covariates \mathbf{X}_{si} .

These estimated log HRs can be combined over studies using random-effects meta-analysis,¹² which incorporates heterogeneity between studies as described below. Fixed-effects meta-analysis can also be used,^{3,13,14} and has been employed in parallel analyses in the ERFC. Writing the variance of the estimated β_s as v_s , the random-effects meta-analysis model is:

$$\begin{aligned} \hat{\beta}_s &= \beta_s + \varepsilon_s; \text{ where } \varepsilon_s \sim N(0, v_s) \\ \beta_s &= \beta + \eta_s; \text{ where } \eta_s \sim N(0, \tau^2) \end{aligned} \quad (2)$$

Here β is the average log HR, the estimate of which combines within-study information on the relationship between exposure and risk, while allowing for heterogeneity in the true log HRs between studies as represented by the variance τ^2 . A standard moment estimator of τ^2 is used,¹⁵ although other estimation methods are available.¹⁶ The statistical significance of the standard test for heterogeneity¹⁷ reflects the strength of evidence for heterogeneity. The impact of heterogeneity on the imprecision of the overall log hazard ratio is expressed in terms of I^2 , the percentage of variance in the point estimates of the study-specific log HRs that is attributable to between-study variation as opposed to sampling variation,¹⁸ for which a confidence interval is

also available.¹⁹ Values of I^2 close to 0% correspond to lack of heterogeneity. In addition, specific sources of heterogeneity are explored by investigating the impact of various factors (eg, age, sex and other potential effect modifiers) on the strength of the association between exposure and risk, as described in later sections.

The above procedure is a 2-step method: first each study is analysed separately in (1) and then the log HRs are combined in (2). A 1-step method would be preferable in principle, writing a combined model as:

$$\begin{aligned} \log(h_{ski}(t | E_{si}, X_{si})) &= \log h_{0sk}(t) + \beta_s E_{si} + \gamma_s X_{si} \\ \beta_s &= \beta + \eta_s; \text{ where } \eta_s \sim N(0, \tau^2) \end{aligned} \quad (3)$$

Computational problems are, however, formidable in a dataset the size of the ERFC.²⁰ A 2-step analysis has only the slight disadvantage that the first-step variances v_s in a 2-step analysis are not in general exactly those implied in a 1-step method, although 1-step and 2-step methods usually produce very similar results.^{21,22}

For the case of fibrinogen and the risk of CHD, adjusting only for the linear effect of age at baseline in each study, these analyses are summarised in the upper part of **Table 1**. The study-specific HRs are shown in **Figure 1**. The random-effects combined HR $\exp(\beta)$ is estimated as 1.57 (95% CI 1.47 to 1.67) per 1g/L higher baseline fibrinogen concentration, and an I^2 of 64% (95% CI 48% to 76%) indicates substantial heterogeneity across studies (test for heterogeneity, $P < 0.0001$). By comparison, a fixed-effects meta-analysis estimate gives a lower point estimate of 1.52 with a narrower 95% CI of 1.47 to 1.57.

The above estimates and CIs relate to the overall mean HR across all studies. Also of interest is the range of true HRs across studies, representing those in different contexts or populations. It can be expressed by the 95% prediction interval for the true HR in a new study, and estimated from the random-effects meta-analysis by $\exp(\hat{\beta} \pm t_{s-2} \sqrt{\text{Var}(\hat{\beta}) + \hat{\tau}^2})$ where t is the 2.5-percentile of a t-distribution and S the number of studies.¹² In the case of the fibrinogen data, this 95% prediction interval is 1.18 to 2.08. Because of the presence of heterogeneity, this

1
2
3 interval is much wider than the 95% CI for $\exp(\beta)$, as shown at the bottom of **Figure 1**, but
4
5 remains above 1 indicating that the relationships in different studies are consistently positive.
6
7

8 9 **Choice of exposure scale**

10
11
12 An assumption of the above model is that the log hazard increases linearly with the exposure. It
13
14 might be more appropriate, however, to choose a log scale for some exposures to improve
15
16 linearity. Alternatively, the use of a study-specific standard deviation (SD) score might reduce
17
18 heterogeneity of the risk association between studies. In the case of fibrinogen, for example, the
19
20 distributions were slightly positively skewed and the SDs varied considerably between studies.²³
21
22 It is also important to assess the possibility of non-linear risk relationships which could indicate a
23
24 threshold or a plateau for risk.
25

26
27 To assess linearity, as in previous studies,³ the distributions of the exposure are divided into
28
29 quantile groups such as fifths; such quantile groups can be defined within each study or across all
30
31 studies. HRs in each quantile group, compared to the bottom group, are estimated using Cox PH
32
33 regression in each study separately. These log HRs within each study are not independent (their
34
35 correlations are available from standard regression software) because they are all relative to the
36
37 same reference group. So the set of log HRs are pooled across studies using a multivariate
38
39 version of random-effects meta-analysis^{24,25} to allow for their inter-correlations both within and
40
41 between studies. These pooled log HRs are plotted against the mean exposure level in each
42
43 quantile group. Assessing linearity is easier using confidence intervals derived by floating
44
45 absolute risk methods^{26,27} so that each estimate (including that for the reference category) has a
46
47 measure of uncertainty and is less correlated with the others. Judging linearity visually from
48
49 strongly correlated estimates can be misleading: for example, if the reference group is small then
50
51 all the standard confidence intervals will be wide and non-linearity cannot be ruled out.
52
53 Sensitivity analyses, employing different scales for the exposure (eg, log, SD-score) or assessing
54
55 curvature using polynomial terms, are also used to investigate whether heterogeneity between
56
57 studies is reduced or the substantive conclusions affected.
58
59
60

1
2
3 **Figure 2** shows the results of an analysis by study-specific fifths of fibrinogen in relation to
4 CHD risk, which suggests that a log-linear model for risk is satisfactory.¹⁰ Examples of
5 sensitivity analyses are shown in the lower part of **Table 1**. These compare untransformed
6 fibrinogen, log fibrinogen, study-specific SD fibrinogen score, and study-specific SD log
7 fibrinogen score. For comparability, results are expressed as the HR per 1-SD higher baseline
8 fibrinogen; in the first two analyses this refers to the pooled within-study SD (0.65g/L for
9 untransformed fibrinogen). The results from all analyses are quantitatively similar, including the
10 extent of heterogeneity. Including a quadratic term for untransformed fibrinogen in the first
11 analysis provides little evidence of curvature in the risk relationship (P=0.09). In the case of
12 fibrinogen, therefore, the heterogeneity between studies is not due to the choice of exposure scale.
13
14
15
16
17
18
19
20
21
22

23 A few technical issues in such analyses merit consideration. First, the visual assessment of
24 linearity and the comparison between different exposure scales are informal. Secondly, while it
25 might be preferable to use fractional polynomials²⁸ or splines²⁹ to investigate curvature, this is
26 not straightforward in a 2-step random-effects meta-analysis because different functional forms
27 might be appropriate for different studies. These problems would be reduced if a 1-step meta-
28 analysis method were computationally feasible. Thirdly, in **Figure 2**, the choice of fifths is
29 rather arbitrary, and it is not entirely clear what levels of fibrinogen the log HRs should be
30 plotted against; for example, this could be the mean fibrinogen in each fifth weighted by the
31 number of events rather than by the number of participants. Finally, the effect of measurement
32 error and within-person variation in fibrinogen may distort the shape of the exposure-disease
33 relationship, as discussed later.
34
35
36
37
38
39
40
41
42
43

44 **Covariate adjustment**

45
46
47 Age is the most important confounder in many epidemiological applications, and so adjustment
48 for age demands particular attention. For linear terms, age-at-baseline in a PH model is
49 equivalent to including current age as a time-dependent variable, but the latter is computationally
50 more difficult to fit. Assuming a simple linear term for age at baseline may, however, be
51 inadequate, resulting in residual confounding. Alternatives include adjustment or stratification
52 by age categories at baseline, and inclusion of polynomial terms and interactions with other
53
54
55
56
57
58
59
60

1
2
3 covariates (especially sex). Empirical comparison of alternatives as sensitivity analyses is useful
4
5 to check for adequate age adjustment. In principle similar considerations apply to other
6
7 covariates, but in practice the use of linear terms is usually sufficient unless the covariates are
8
9 both highly prognostic and substantially correlated with the exposure of interest. One important
10
11 practical problem often encountered is that not all studies measure all the desired confounders;
12
13 an approach to this situation is described in the Discussion.

14
15
16 The ERFC's 2-step approach allows the confounding effects (γ_s in model 1) to be different in
17
18 each study. Examples of age and other confounder adjustments for fibrinogen dataset are given
19
20 in **Table 2**. In this case, linear adjustment for age at baseline appears to be adequate, because
21
22 more complex forms of adjustment hardly change the results. No precision is lost by
23
24 stratification using narrow age bands. The overall HR for fibrinogen is reduced towards unity on
25
26 adjusting for four additional covariates (last row of **Table 2**), and the extent of heterogeneity
27
28 decreases. Thus some of the original heterogeneity between studies seems to be due to differing
29
30 impacts of these confounders in different studies. The age-adjusted HR per 1g/L higher baseline
31
32 fibrinogen falls from 1.57 to 1.38 on adjusting for these covariates, so that 29% (calculated as
33
34 $[\log 1.57 - \log 1.38] / \log 1.57$) of the effect is 'explained' by the observed values of these
35
36 confounders. The change in the respective Wald χ^2_1 statistics reflects a slight decrease in the
37
38 strength of evidence for an association.³

39 **Joint effects**

40
41
42
43 An important advantage of IPD is that it provides the opportunity for systematic investigation of
44
45 the exposure-risk relationship at different levels of other variables. This evaluation of factors
46
47 that modify the overall log HRs estimated above involves assessing their interactions on this
48
49 scale with the exposure of interest. When effect modifiers are variables measured in individuals,
50
51 such as age or other risk markers, these interactions are most effectively assessed using within-
52
53 study information.^{4,30} Here a 2-step procedure has again been adopted, first estimating the
54
55 interaction in each study separately. For example, for a single potential effect modifier X_{si} , the
56
57 model in study s is:

$$58 \log(h_{ski}(t | E_{si}, X_{si})) = \log h_{0sk}(t) + \beta_s E_{si} + \gamma_s X_{si} + \delta_s E_{si} X_{si} \quad (4)$$

59
60

The estimates of the interaction terms δ_s are combined using random-effects meta-analysis, as in (2). The overall interaction, δ_W say, is then based on only within-study information. Model (4) can be extended by including adjustments for other confounders, and indeed their interactions with the exposure of interest; this enables investigation of whether, as is possible, a particular interaction is confounded by other main effects or interactions.

Some potential effect modifiers are assessed only at the study level, for example the type of population recruited or the laboratory methods used for measuring the exposure. For such variables, any information on interactions relies entirely on between-study comparisons, which are assessed using random-effects meta-regression.³¹ Using the estimates of β_s from (1), model (2) is extended to include a study level covariate X_s by writing:

$$\begin{aligned}\hat{\beta}_s &= \beta_s + \varepsilon_s; \text{ where } \varepsilon_s \sim N(0, s_s^2) \\ \beta_s &= \beta + \delta_B X_s + \eta_s; \text{ where } \eta_s \sim N(0, \tau^2)\end{aligned}\tag{5}$$

δ_B is the between-study interaction term, with statistical significance assessed allowing for the residual between-study heterogeneity τ^2 .

A few variables, notably sex and ethnic group, have potential interactions for which both within-study and between-study information may be important. For example, studies involving both men and women provide within-study information on sex interactions, while studies which comprise members of one sex alone can only be used to assess interactions across studies. In this case, the within-study interaction δ_W is estimated as in model (4) based on studies of both sexes, and the between-study interaction δ_B using model (5) in which X_s is the proportion of women in each study. Provided they are similar, these two asymptotically independent estimates of interaction can themselves be combined. As between-study information on interactions is prone to numerous potential sources of between-study confounding,³² there is a trade-off between increased precision and possible bias in choosing whether to use between-study information in addition to within-study information.^{22,33,34}

Presenting interactions in a way that is intelligible to readers is not easy. For a binary variable identifying two subgroups, the exponent of the interaction term is a ratio of HRs, but it is simpler

1
2
3 to present two separate meta-analyses, one in each subgroup. However, because the between-
4 study heterogeneity, τ^2 in (2), now affects each of these estimates, the (multivariate) meta-
5 analytic weighting of study-specific subgroup estimates is different from the weighting of study-
6 specific interactions. So neither the estimates nor the confidence intervals of the subgroup-
7 specific estimates are necessarily compatible with the estimate and confidence interval of the
8 interaction term. In practice, this problem is not usually severe. For continuous variables, the
9 exponent of the interaction term is a ratio of HRs per unit increase in the effect modifier.
10 Similarly, for presentation, it is easier to present the HR estimates according to study-specific
11 quantile groups (for example thirds or fifths) of the effect modifier distribution.
12
13
14
15
16
17
18
19

20
21 Examples of interaction analyses for fibrinogen are shown in **Table 3**. The interactions with
22 body mass index and age at baseline are clear, but the interactions with other variables are less
23 marked. Including the body mass index and age interactions simultaneously hardly affects their
24 respective estimates. There is more consistency in the interaction terms across studies than for
25 the main effect of fibrinogen, as indicated by the lower values of I^2 . For investigating a possible
26 sex interaction, δ_B is estimated from a meta-regression of the study-specific log HRs on the
27 proportion of women in each study. The SE of the interaction term is smaller for δ_W than δ_B , so
28 the majority (73%) of the information comes from within-study information. It is sensible to rely
29 on the within-study pooled interaction estimate, especially when it contributes the majority of the
30 information, because of the potential for bias in the between-study estimate.²² The sex-specific
31 combined log HRs (not shown) and the combined sex interaction term are similar but not
32 identical. The sex interaction term represents the correct analysis, while the sex-specific HRs are
33 probably the preferable method of presentation in applied publications, especially when given in
34 a diagram. As noted above, effect modification is being assessed on the HR scale. Thus, while
35 the HRs per unit higher fibrinogen decrease with increasing age, the absolute risk gradients
36 increase (**Figure 3**).
37
38
39
40
41
42
43
44
45
46
47
48
49

50 51 **Proportional hazards**

52
53
54
55 An assumption of all the models considered so far is of proportional hazards (PH), meaning that
56 the regression coefficients in model (1) do not change with time since baseline measurement.
57
58
59
60

1
2
3 While the effect of any covariate measured at baseline may plausibly decrease over time, the
4 prime interest is whether the proportional hazards assumption is appropriate for the exposure of
5 interest. This can be evaluated in each study separately by including an interaction between the
6 exposure and time, or by the commonly used diagnostic based on Schoenfeld residuals.³⁵ These
7 independent χ^2_1 statistics can be summed across the S studies, yielding a χ^2_5 statistic testing the
8 hypothesis that PH holds in each study.
9
10
11
12
13
14

15
16 This approach is, however, not a powerful test against the plausible alternative hypothesis that
17 HRs tend to decline over time in all studies. A better method is to combine the interaction terms
18 between the exposure and time over studies. Using random-effects meta-analysis, and assuming
19 linear time-dependence, the model is:
20
21
22

$$\begin{aligned} \log(h_{ski}(t | E_{si}, X_{si})) &= \log h_{0sk}(t) + \beta_s E_{si} + \xi_s t E_{si} \\ \xi_s &= \xi + \eta_s; \text{ where } \eta_s \sim N(0, \tau^2) \end{aligned} \quad (6)$$

23
24
25 where β_s are separate fixed effects, and the focus is on the estimate of ξ which can be tested
26 using a χ^2_1 statistic.
27
28
29
30
31
32

33 The results of these analyses for fibrinogen are shown in **Table 4**. The summed χ^2_{31} statistics are
34 less than expectation, as is the more powerful χ^2_1 statistic. So, in this case (and perhaps
35 surprisingly given the extent of data), there is no evidence of departures from proportional
36 hazards for fibrinogen and no evidence of heterogeneity between studies in this regard. The final
37 method provides an estimate of the non-PH parameter ξ , which indicates that over a 20-year
38 period the estimated change in the exposure log HR is small. In ERFC, this random-effects
39 pooling of the interaction terms between exposure and time is used to assess the PH assumption.
40 It provides extra power against a plausible alternative hypothesis, and is consistent with the
41 approach described above for quantifying other interactions. If there was substantial evidence
42 against the PH assumption, it would be necessary to summarise the exposure-risk relationship
43 either in discrete intervals of time, or as a trend over time.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Other topics

When the focus is on estimating underlying aetiological associations, it is necessary to adjust for the effect of measurement error and within-person variation. For the exposure of interest, this addresses the often serious underestimation caused by regression dilution bias,^{9,36,37} and for covariates it reduces residual confounding.³⁸ Methods exist to correct for regression dilution bias in exposure variables in IPD meta-analysis.^{3,13,14} Novel methods that enable concurrent adjustment for measurement error both in the exposure of interest and in covariates have been developed for use in the multiple study context of the ERFC, but they are technically demanding and have been described in full elsewhere.^{39,40} Examples of these analyses for fibrinogen are shown in **Table 5**. Since the within-person correlation of fibrinogen measurements on different occasions is about 0.5,³⁹ the overall log HR corrected for measurement error in fibrinogen alone is about twice the uncorrected estimate (leading to a corrected HR of 1.96 vs 1.38 uncorrected). Multivariate correction for measurement error in four confounders makes the log HR for fibrinogen slightly less extreme, as expected because residual confounding is reduced, with an estimated HR of 1.85 per 1g/L higher “usual” (ie, long-term average) fibrinogen level. As methods that correct for regression dilution cannot correct for unmeasured covariates, residual confounding may persist after their use.

Some cohorts in the ERFC have analysed particular risk markers in a nested case-control or case-cohort design. Nested case-control studies are analysed with similar methods to those described for cohort studies, but they involve logistic regression.⁴¹ For individually-matched studies, conditional logistic regression is appropriate. For frequency-matched studies, ordinary logistic regression is used with the matching factors as covariates. Such analyses either provide estimates of HRs (if matched controls were selected to be disease-free at the time the case had an event), or odds ratios (if the selected controls were disease-free at the end of the study).⁴² Provided the disease is relatively rare (say fewer than 10% of the study’s participants), odds ratios approximate HRs and it is reasonable to combine them in a meta-analysis. For nested case-cohort studies, the analysis should allow for the fact that some members of the randomly selected cohort also become cases.⁴³ A modified PH regression model then provides estimates of

1
2
3 log HRs with robust standard errors,⁴⁴ although this modification generally has only a small
4 effect.
5
6

7
8 Although some participants may have multiple events (eg, two CHD events at separate time
9 points, or a CHD event followed by another type of event, such as a stroke or death from cancer),
10 analyses in the ERFC focus on first events by censoring participants after their first CHD event,
11 after another non-fatal event such as stroke (when cohorts have recorded them), and after death
12 from any cause. The rationale for this approach is that major cardiovascular disease events may
13 disrupt the association between baseline risk factors and subsequent disease risk. The ERFC
14 does not, however, censor individuals at the time of cardiovascular investigations or
15 interventions (such as angiography or coronary bypass operations) or at the diagnosis of angina
16 because the incidence of such occurrences is not recorded reliably enough in sufficient studies.
17 Sensitivity analyses that implement alternative censoring criteria can assess potential biases that
18 might arise through these decisions on censoring.
19
20
21
22
23
24
25
26
27
28
29

30 The constraints on comprehensiveness in IPD meta-analyses mainly relate to the identification of
31 relevant studies and provision of data. In the ERFC, studies have been identified from
32 publications, extensive literature searches, and correspondence with authors of relevant reports.
33 The ERFC has included the large majority of Western prospective studies with any relevant
34 exposure markers and >20,000 person-years of follow-up. Hence, although publication and
35 reporting biases are potential concerns in all meta-analyses, they may be less so in the ERFC.
36
37
38
39
40
41

42 **DISCUSSION**

43
44
45 The statistical methods used in the ERFC have been explicitly described and illustrated in this
46 report to facilitate their adoption by others; example programs in Stata⁴⁵ are available from
47 www.phpc.cam.ac.uk/MEU/ERFC/Software.html. The ERFC methods extend previous
48 approaches in several respects.⁴⁶⁻⁴⁸ Strategies being used in the ERFC to adjust for measurement
49 error concurrently in levels of both confounders and exposures should help to improve estimates
50 of the underlying aetiological association between exposures and disease outcomes by reducing
51 residual confounding. Methods used in the ERFC give specific consideration to the analysis of
52
53
54
55
56
57
58
59
60

1
2
3 interactions for characteristics that vary both within and between studies, and to assessment of
4 the proportional hazards assumption.
5
6
7

8
9 A common practical problem in IPD meta-analyses is how to adjust for confounders which are
10 measured only in a subset of the studies. For the fibrinogen example, age and four other
11 confounders (**Table 2**) were measured in all participants in all studies. However, additional
12 confounders, such as lipid fractions (HDL-C, LDL-C and triglycerides), were available in only
13 about half of the studies.¹⁰ More comprehensive adjustment for confounding can only be easily
14 achieved by restricting the dataset to the latter studies, but such restriction omits information on
15 partial adjustment from the other studies. We have previously described an approach that uses
16 the partially adjusted HRs, which can be estimated in all studies, and the more comprehensively
17 adjusted log HRs, which can be estimated only in a subset of studies, in a bivariate meta-
18 analysis.⁴⁹ This approach acknowledges the correlations between the partially and the more
19 comprehensively adjusted log HRs within studies where both can be estimated, but uses the full
20 dataset to contribute to the estimation of a combined more comprehensively adjusted log HR.
21
22
23
24
25
26
27
28
29
30

31
32 An unresolved issue concerns the estimation of a possibly non-linear exposure-risk relationship
33 when the exposure is measured with error. Homogeneous measurement error, with a variance
34 that does not depend on level of the exposure, will tend to make a non-linear association appear
35 more linear. Conversely, measurement error that, for example, increases with level of the
36 exposure will make a linear association appear non-linear. Characterising the shape of the
37 underlying exposure-disease relationship, while taking into account possibly heterogeneous
38 measurement error, is not well-studied, especially in the context of IPD meta-analysis.⁵⁰ One
39 approach may be to model the underlying association using fractional polynomials or splines,
40 while carefully estimating measurement error variance as a function of exposure level.
41
42
43
44
45
46
47
48

49
50 As distinct from characterising the shape, magnitude and independence of associations between
51 risk factors and disease (which may be relevant to judgements about an exposure's potential
52 aetiological relevance), IPD meta-analyses of multiple studies can provide additional useful
53 information. For example, we have previously described the ERFC's approach to characterising
54 the cross-sectional correlates (and, hence, potential determinants) of risk markers.²³ Although
55
56
57
58
59
60

1
2
3 this paper has not addressed issues related to risk prediction (ie, the extent to which measuring an
4 additional exposure could better identify the risk of disease outcomes for individuals), there is
5 considerable interest in the use of information from multiple prospective studies to help inform
6 risk stratification and/or screening strategies. A separate literature exists which involves
7 risk stratification and/or screening strategies. A separate literature exists which involves
8 discussion of how the “area under an ROC curve” can be adapted for time-to-event data⁵¹ and the
9 extent to which individuals are re-classified into risk groups that would affect the subsequent
10 intervention offered.^{52,53} We have adapted and illustrated some of these predictive metrics for
11 use in the multiple study situation,⁵⁴ and further such work comprises a future methodological
12 research agenda.
13
14
15
16
17
18
19

20 Increasing numbers of IPD meta-analyses of observational data are being conducted in order to
21 enhance the statistical power and detail of epidemiological studies. The scientific value of such
22 approaches has now been demonstrated in relation to a variety of exposures and disease
23 outcomes in many different consortia, exemplified by the Prospective Studies Collaboration,³ the
24 Asia Pacific Cohort Studies Collaboration,⁵⁵ the Breast Cancer Genetics Linkage Consortium,⁵⁶
25 the Collaborative Group on Hormonal Factors in Breast Cancer,⁵⁷ the US Pooling Project of
26 Prospective Studies of Diet and Cancer⁴⁷ and the GENOMOS Genetic Markers for Osteoporosis
27 Consortium.⁵⁸ The statistical methods developed here can be used to address the needs of such
28 analyses. Appropriate meta-analytical methods may also have applications to analyses of large
29 purpose-designed multi-centre prospective observational studies, such as the pan-European EPIC
30 study,⁵⁹ UK Biobank^{60,61} and the subsequent planned meta-analysis of such studies.⁶²
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **List of Authors** (Appendix 1 in reference 5 lists the study acronyms):
4

5 **Writing Committee:** SG Thompson DSc, MRC Biostatistics Unit, UK; S Kaptoge PhD, University of Cambridge, UK;
6 IR White MSc, MRC Biostatistics Unit, UK; AM Wood PhD, University of Cambridge, UK; PL Perry MBChB, University
7 of Cambridge, UK; J Danesh FRCP, University of Cambridge, UK.
8

9 **Author contributions:** All authors contributed to the conception and design of this work; SGT and IRW proposed
10 the methods; SK and PLP analysed the data; SGT drafted the paper; all authors critically revised the paper and
11 approved the final version. SGT is the guarantor. The authors declare no conflicts of interest.

12 **Investigators / Contributors:** **AFTCAPS:** RW Tipping MS, Merck Research Laboratories, USA; **ALLHAT:** CE Ford
13 PhD, University of Texas School of Public Health, USA; LM Simpson PhD, University of Texas School of Public Health,
14 USA; **AMORIS:** G Walldius MD, Karolinska Institutet, Sweden; I Jungner MD, Karolinska Institutet, Sweden; **ARIC:**
15 LE Chambless PhD, University of North Carolina, USA; **ATTICA:** DB Panagiotakos MD, Harokopio University,
16 Greece; C Pitsavos MD, University of Athens, Greece; C Chrysohoou MD, University of Athens, Greece; C
17 Stefanadis MD, University of Athens, Greece; **BHS:** M Knuiman PhD, University of Western Australia, Australia;
18 **BIP:** U Goldbourt PhD, Sheba Medical Center, Israel; M Benderly PhD, Sheba Medical Center, Israel; D Tanne MD,
19 Sheba Medical Center, Israel; **BRHS:** PH Whincup FRCP, University of London, UK; SG Wannamethee PhD,
20 University College London, UK; RW Morris PhD, University College London, UK; **BRUN:** J Willeit MD, Medical
21 University Innsbruck, Austria; S Kiechl MD, Medical University Innsbruck, Austria; P Santer MD, Bruneck Hospital,
22 Italy; A Mayr MD, Bruneck Hospital, Italy; **BWHHS:** DA Lawlor PhD, University of Bristol, UK; **CaPS:** JWG Yarnell
23 MD, Queen's University of Belfast, UK; J Gallacher PhD, Cardiff University, UK; **CASTEL:** E Casiglia MD, University
24 of Padova, Italy; V Tikhonoff MD, University of Padova, Italy; **CHARL:** PJ Nietert PhD, Medical University of South
25 Carolina, USA; SE Sutherland PhD, Medical University of South Carolina, USA; DL Bachman MD, Medical University
26 of South Carolina, USA; JE Keil DrPH, Medical University of South Carolina, USA; **CHS:** M Cushman MD, University
27 of Vermont, USA; RP Tracy PhD, University of Vermont, USA; (see <http://chs-nhlbi.org> for acknowledgements);
28 **COPEN:** A Tybjaerg-Hansen MD, University of Copenhagen, Denmark; BG Nordestgaard MD, University of
29 Copenhagen, Denmark; M Benn MD, University of Copenhagen, Denmark; R Frikke-Schmidt MD, University of
30 Copenhagen, Denmark; **CUORE:** S Giampaoli MD, Istituto Superiore di Sanità, Italy; L Palmieri DrStat, Istituto
31 Superiore di Sanità, Italy; S Panico MD, Federico II University, Italy; D Vanuzzo MD, Centre for Cardiovascular
32 Prevention, Italy; **DRECE:** A Gómez de la Cámara MD, Hospital 12 de Octubre, Spain; JA Gómez-Gerique PhD,
33 Hospital Marqués de Valdecilla, Spain; **DUBBO:** L Simons MD, University of NSW, Australia; J McCallum DPhil,
34 Victoria University, Melbourne, Australia; Y Friedlander PhD, Hebrew University, Israel; **EAS:** FGR Fowkes MBChB,
35 University of Edinburgh, UK; AJ Lee PhD, University of Edinburgh, UK; **EPESEBOS:** J Taylor MD, East Boston
36 Neighborhood Health Center, USA; JM Guralnik MD, US National Institute on Aging, USA; **EPESEIOW:** R Wallace
37 MD, University of Iowa, USA; J Guralnik MD, US National Institute on Aging, USA; **EPESENCA:** DG Blazer MD,
38 Duke University Medical Centre, USA; JM Guralnik MD, US National Institute on Aging, USA; **EPESENHA:** JM
39 Guralnik MD, US National Institute on Aging, USA; **EPICNOR:** K-T Khaw MBBChir, University of Cambridge, UK;
40 **ESTHER:** H Brenner MD, German Cancer Research Center, Germany; E Raum MD, German Cancer Research
41 Center, Germany; H Müller DrScHum, German Cancer Research Center, Germany; D Rothenbacher MD, German
42 Cancer Research Center, Germany; **FIA:** JH Jansson MD, Umeå University, Sweden; P Wennberg MD, Umeå
43 University, Sweden; **FINE_FIN:** A Nissinen MD, National Institute for Health and Welfare, Finland; **FINE_IT:** C
44 Donfrancesco DrStat, Istituto Superiore di Sanità, Italy; S Giampaoli MD, Istituto Superiore di Sanità, Italy;
45 **FINRISK92, FINRISK97:** V Salomaa MD, National Institute for Health and Welfare, Finland; K Harald MA,
46 National Institute for Health and Welfare, Finland; P Jousilahti MD, National Institute for Health and Welfare,
47 Finland; E Vartiainen MD, National Institute for Health and Welfare, Finland; **FLETCHER:** M Woodward PhD, Mount
48 Sinai School of Medicine, USA; **FRAMOFF:** RB D'Agostino PhD, Boston University, USA; RS Vasan MD, Boston
49 University School of Medicine, USA; MJ Pencina PhD, Boston University School of Medicine, USA; **GLOSTRUP:** EM
50 Bladbjerg PhD, University of Southern Denmark, Denmark; T Jørgensen, MD, University of Copenhagen, Denmark;
51 L Møller MD, World Health Organization; J Jespersen DSc, University of Southern Denmark, Denmark; **GOH:** R
52 Dankner MD, Gertner Institute for Epidemiology and Health Policy Research, Israel; A Chetrit MSc, Gertner
53 Institute for Epidemiology and Health Policy, Israel; F Lubin RD, Gertner Institute for Epidemiology and Health
54 Policy, Israel; **GOTO33, GOTO43:** A Rosengren MD, Göteborg University, Sweden; G Lappas BSc, Göteborg
55 University, Sweden; **GOTOW:** C Björkelund MD, Göteborg University, Sweden; L Lissner PhD, Göteborg University,
56 Sweden; C Bengtsson MD, Göteborg University, Sweden; **GRIPS:** P Cremer MD, Klinikum der Universität München
57 LMU, Germany; D Nagel PhD, University of Munich, Germany; **HELSINAG:** RS Tilvis MD, Helsinki University
58 Hospital, Finland; TE Strandberg MD, Oulu University Hospital, Finland; **HISAYAMA:** Y Kiyohara MD, Kyushu
59 University, Japan; H Arima MD, Kyushu University, Japan; Y Doi MD, Kyushu University, Japan; T Ninomiya MD,
60 Kyushu University, Japan; **HONOL:** B Rodriguez MD, University of Hawaii, USA; **HOORN:** JM Dekker PhD, VU
University Medical Center, The Netherlands; G Nijpels MD, Vrije Universiteit Medical Center, The Netherlands; CDA
Stehouwer MD, Maastricht University Medical Centre, The Netherlands; **HPFS:** E Rimm ScD, Harvard University,
USA; JK Pai ScD, Brigham and Women's Hospital, USA; **IKNS:** S Sato MD, Osaka Medical Center for Health Science
and Promotion, Japan; H Iso MD, Osaka University, Japan; A Kitamura MD, Osaka Medical Center for Health
Science and Promotion, Japan; H Noda MD, Osaka University, Japan; **ISRAEL:** U Goldbourt PhD, Sheba Medical
Center, Israel; **NORTH KARELIA:** V Salomaa MD, National Institute for Health and Welfare, Finland; K Harald MA,

National Institute for Health and Welfare, Finland; P Jousilahti MD, National Institute for Health and Welfare, Finland; E Vartiainen MD, National Institute for Health and Welfare, Finland; **KIHD**: JT Salonen MD, University of Kuopio, Finland; T-P Tuomainen MD, University of Kuopio, Finland; **LASA**: DJH Deeg MD, VU University Medical Centre, The Netherlands; JL Poppelaars, VU University Medical Centre, The Netherlands; **LEADER**: TW Meade FMedSci, London School of Hygiene and Tropical Medicine, UK; JA Cooper MSc, University College London, UK; **MALMO**: B Hedblad MD, Lund University, Sweden; G Berglund MD, Lund University, Sweden; G Engstrom MD, Lund University, Sweden; **MCVDRFP**: WMM Verschuren PhD, National Institute of Public Health and the Environment, The Netherlands; A Blokstra MSc, National Institute for Public Health and the Environment, The Netherlands; **MESA**: M Cushman MD, University of Vermont, USA; S Shea MD, Columbia University, USA; **MOGERAUG1, MOGERAUG2, MOGERAUG3**: A Döring MD, German Research Center for Environmental Health, Germany; W Koenig MD, University of Ulm Medical Center, Germany; C Meisinger MD, German Research Center for Environmental Health, Germany; W Mraz MD, Klinikum der Universität München, Institute of Clinical Chemistry, Munich, Germany; **MORGEN**: WMM Verschuren PhD, National Institute of Public Health and the Environment, The Netherlands; A Blokstra MSc, National Institute for Public Health and the Environment, The Netherlands; H Bas Bueno-de-Mesquita PhD, National Institute for Public Health and the Environment, The Netherlands; **MOSWEGOT**: A Rosengren MD, Göteborg University, Sweden; G Lappas MD, Göteborg University, Sweden; **MRFIT**: LH Kuller MD, University of Pittsburgh, USA; G Grandits MS, University of Minnesota, USA; **NCS**: R Selmer PhD, Norwegian Institute of Public Health, Norway; A Tverdal PhD, Norwegian Institute of Public Health, Norway; W Nystad PhD, Norwegian Institute of Public Health, Norway; **NHANES I, NHANES II, NHANES III**: R Gillum MD, Centers for Disease Control and Prevention, USA; M Mussolino PhD, National Institutes of Health, USA; **NHS**: E Rimm ScD, Harvard University, USA; S Hankinson ScD, Harvard School of Public Health, USA; JE Manson MD, Harvard Medical School, USA; JK Pai ScD, Brigham and Women's Hospital, USA; **NPHS I**: TW Meade FMedSci, London School of Hygiene and Tropical Medicine, UK; JA Cooper MSc, University College London, UK; C Knottenbelt, MD; **NPHS II**: JA Cooper MSc, University College London, UK; KA Bauer MD, Harvard Medical School, USA; **OSAKA**: S Sato MD, Osaka Medical Center for Health Science and Promotion, Japan; A Kitamura MD, Osaka Medical Center for Health Science and Promotion, Japan; Y Naito MD, Mukogawa Women's University, Japan; H Iso MD, Osaka University, Japan; **OSLO**: I Holme PhD, Oslo University Hospital, Norway; R Selmer PhD, Norwegian Institute of Public Health, Norway; A Tverdal PhD, Norwegian Institute of Public Health, Norway; W Nystad PhD, Norwegian Institute of Public Health, Norway; **OYABE**: H Nakagawa MD, Kanazawa Medical University, Japan; K Miura MD, Shiga University of Medical Science, Japan; **PARIS1**: P Ducimetiere PhD, INSERM, France; X Jouven MD, INSERM, France; **PRHHP**: CJ Crespo DrPH, Portland State University, USA; MR Garcia Palmieri MD, University of Puerto Rico, USA; **PRIME**: P Amouyel MD, Institut Pasteur de Lille, France; D Arveiler MD, Université de Strasbourg, France; A Evans MD, The Queens University of Belfast, UK; J Ferrieres MD, University of Toulouse, France; **PROCAM**: H Schulte PhD, Assmann-Stiftung für Prävention, Germany; G Assmann FRCP, Assmann-Stiftung für Prävention, Germany; **PROSPER**: J Shepherd MD, Glasgow Royal Infirmary, UK; CJ Packard DSc, University of Glasgow, UK; N Sattar FRCPATH, University of Glasgow, UK; I Ford PhD, University of Glasgow, UK; **QUEBEC**: B Cantin MD, Institut de Cardiologie de Québec, Hôpital Laval, Canada; J-P Després PhD, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Canada; GR Dagenais MD, Institut universitaire de cardiologie et pneumologie de Québec, Canada; **RANCHO**: E Barrett-Connor MD, University of California, USA; DL Wingard PhD, University of California, USA; R Bettencourt MS, University of California, USA; **REYK**: V Gudnason MD, University of Iceland, Iceland; T Aspelund PhD, University of Iceland, Iceland; G Sigurdsson MD, University of Iceland, Iceland; B Thorsson MD, Icelandic Heart Association, Iceland; **RIFLE**: M Trevisan MD, Nevada System of Higher Education, USA; **ROTT**: J Witteman PhD, Erasmus MC, The Netherlands; I Kardys MD, Erasmus MC, the Netherlands; M Breteler MD, Erasmus MC, The Netherlands; A Hofman MD, Erasmus MC, The Netherlands; **SHHEC**: H Tunstall-Pedoe MD, University of Dundee, UK; R Tavendale PhD, University of Dundee, UK; GDO Lowe DSc, University of Glasgow, UK; M Woodward PhD, Mount Sinai School of Medicine, USA; **SPEED**: Y Ben-Shlomo PhD, University of Bristol, UK; G Davey-Smith MD, University of Bristol, UK; **SHS**: BV Howard PhD, Medstar Research Institute, USA; Y Zhang MD, University of Oklahoma Health Sciences Center, USA; J Umans MD, Georgetown University Medical Centre, USA; **TARFS**: A Onat MD, Istanbul University, Turkey; **TPT**: TW Meade FMedSci, London School of Hygiene and Tropical Medicine, UK; **TROMSØ**: T Wilsgaard PhD, University of Tromsø, Norway; **ULSAM**: E Ingelsson MD, Karolinska Institutet, Sweden; L Lind PhD, Department of Medical Sciences, Uppsala University, Uppsala, Sweden; V Giedraitis PhD, Department of Public Health and Geriatrics, Uppsala University Hospital, Uppsala, Sweden; L Lannfelt MD, Department of Public Health and Geriatrics, Uppsala University Hospital, Uppsala, Sweden; **USPHS**: JM Gaziano MD, Brigham and Women's Hospital, USA; P Ridker MD, Brigham and Women's Hospital, USA; **USPHS2**: JM Gaziano MD, Brigham and Women's Hospital, USA; P Ridker MD, Brigham and Women's Hospital, USA; **VHMP**: H Ulmer PhD, Innsbruck Medical University, Austria; G Diem MD, Agency for Preventive and Social Medicine, Austria; **VITA**: A Tosetto MD, San Bortolo Hospital, Italy; F Rodeghiero MD, San Bartolo Hospital, Italy; **WHI**: S Wassertheil-Smoller PhD, Albert Einstein College of Medicine, New York, USA; JE Manson MD, Harvard Medical School, USA; **WHITE I**: M Marmot FMedSci, University College London, UK; R Clarke MD, University of Oxford, UK; R Collins FMedSci, University of Oxford, UK; **WHITE II**: E Brunner PhD, University College London, UK; M Shipley MSc, University College London, UK; **WHS**: P Ridker MD, Brigham and Women's Hospital, USA; J Buring ScD, Brigham and Women's Hospital, USA; **WOSCOPS**: J Shepherd MD, Glasgow Royal Infirmary, UK; SM Cobbe FMedSci, BHF Glasgow Cardiovascular Research Centre, UK; I Ford PhD, University of Glasgow, UK; M Robertson BSc, University of Glasgow, UK; **XIAN**: Y He MD, Chinese PLA General Hospital, China; **ZARAGOZA**: A Marín Ibañez MD, San Jose Norte Health Centre,

Spain; **ZUTE**: EJM Feskens MD, Division of Human Nutrition, Wageningen University, Wageningen, Netherlands; D Kromhout PhD, Division of Human Nutrition, Wageningen University, Netherlands.

Coordinating Centre: R Collins FMedSci, University of Oxford, UK; E Di Angelantonio MD, University of Cambridge, UK; S Erqou MD, University of Cambridge, UK; S Kaptoge PhD, University of Cambridge, UK; S Lewington DPhil, University of Oxford, UK; L Orfei MSc, University of Cambridge, UK; L Pennells MSc, University of Cambridge, UK; PL Perry MBChB, University of Cambridge, UK; KK Ray MD, University of Cambridge, UK; N Sarwar PhD, University of Cambridge, UK; M Alexander MPhil, University of Cambridge, UK; A Thompson PhD, University of Cambridge, UK; SG Thompson DSc, MRC Biostatistics Unit, UK; M Walker PhD, University of Cambridge, UK; S Watson MMath, University of Cambridge, UK; F Wensley MSc, University of Cambridge, UK; IR White MSc, MRC Biostatistics Unit, UK; AM Wood PhD, University of Cambridge, UK; J Danesh FRCP, University of Cambridge, UK (principal investigator).

Funding: Methodological work in the ERFC has been supported by specific grants from the UK Medical Research Council. The ERFC Coordinating Centre is underpinned by a programme grant from the British Heart Foundation and supported by the BUPA Foundation and unrestricted educational grants from GlaxoSmithKline. A variety of sources have supported recruitment, follow-up and laboratory measurements in the cohorts contributing to the ERFC. Investigators of several of these studies have contributed to a list naming some of these funding sources, which can be found at <http://www.phpc.cam.ac.uk/MEU/>.

References

1. Egger M, Davey Smith G, Altman DG [editors]. *Systematic reviews in health care: meta-analysis in context*. London: BMJ Books; 2001.
2. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. *Stat Med* 1995; **14**: 2057-2079.
3. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**: 1903-1913.
4. Thompson SG, Higgins JPT. Can meta-analysis help target interventions at individuals most likely to benefit? *Lancet* 2005; **365**: 341-346.
5. Emerging Risk Factors Collaboration. Collaborative meta-analysis of individual data on over 1 million participants in 96 prospective cohorts of lipid and inflammatory markers in cardiovascular diseases. *Eur J Epidemiol* 2007; **22**: 839-869.
6. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins and risk of vascular disease. *J Am Med Assoc* 2009; **302**: 1993-2000.
7. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality: individual data analysis of 121,944 participants from 34 prospective studies. *J Am Med Assoc* 2009; **302**: 412-423.
8. Emerging Risk Factors Collaboration. C-reactive protein concentration and the risk of coronary heart disease, stroke and mortality: an individual participant meta-analysis. *Lancet* 2010; **375**: 132-140.
9. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990; **335**: 765-774.
10. Fibrinogen Studies Collaboration. Plasma fibrinogen and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. *JAMA* 2005; **294**: 1799-1809.
11. Cox DR. Regression models and life tables. *J Roy Stat Soc B* 1972; **74**: 187-220.
12. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *J Roy Stat Soc A* 2009; **172**: 137-159.
13. Prospective Studies Collaboration. Collaborative overview ('meta-analysis') of prospective observational studies of the associations of usual blood pressure and usual cholesterol levels

with common causes of death: protocol for the second cycle of the Prospective Studies Collaboration. *J Cardiovasc Risk* 1999; **6**: 315-320.

14. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet* 2007; **370**: 1829-1839.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986; **7**: 177-188.
16. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. *Contemp Clin Trials* 2007; **28**: 105-114.
17. Cochran WG. The combination of estimates from different experiments. *Biometrics* 1954; **10**: 101-129.
18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. *BMJ* 2003; **327**: 557-560.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**: 1539-1558.
20. Tudur-Smith C, Williamson PR, Marson AG. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. *Stat Med* 2005; **24**: 1307-19.
21. Olkin I, Sampson A. Comparison of meta-analysis versus analysis of variance of individual patient data. *Biometrics* 1998; **54**: 317-322.
22. Riley RD, Lambert PC, Staessen JA, Wang J, Gueyffier F, Thijs L, Bouitrie F. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. *Stat Med* 2008; **27**: 1870-1893.
23. Fibrinogen Studies Collaboration. Associations of plasma fibrinogen levels with established cardiovascular risk factors, inflammatory markers and other characteristics: individual participant meta-analysis of 154 211 adults in 31 prospective studies. *Am J Epidemiol* 2007; **166**: 867-879.
24. Riley RD, Abrams KR, Lambert PC, Sutton AJ, Thompson JR. An evaluation of bivariate random-effects meta-analysis for the joint synthesis of two correlated outcomes. *Stat Med* 2007; **26**: 78-97.
25. White IR. Multivariate random-effects meta-analysis. *Stata J* 2009; **9**: 40-56.
26. Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. *Stat Med* 1991; **10**: 1025-1035.

- 1
2
3
4
5 27. Plummer M. Improved estimates of floating absolute risk. *Stat Med* 2004; **23**: 93-104.
- 6
7 28. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous
8 risk variables in epidemiology. *Int J Epidemiol* 1999; **28**: 964-974.
- 9
10 29. Govindarajulu US, Spiegelman D, Thurston SW, Ganguli B, Eisen EA. Comparing
11 smoothing techniques in Cox models for exposure-response relationships. *Stat Med* 2007;
12 26: 3735-3752.
- 13
14 30. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level
15 covariates in meta-regression with individual patient data meta-analysis. *J Clin Epidemiol*
16 2002; **55**: 86-94.
- 17
18 31. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods.
19 *Stat Med* 1999; **18**: 2693-2708.
- 20
21 32. Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and
22 interpreted? *Stat Med* 2002; **21**: 1559-1573.
- 23
24 33. Simmonds MC, Higgins JP. Covariate heterogeneity in meta-analysis: criteria for deciding
25 between meta-regression and individual patient data. *Stat Med* 2007; 26: 2982-2999.
- 26
27 34. Jackson C, Best N, Richardson S. Improving ecological inference using individual-level data.
28 *Stat Med* 2006; 25: 2136-2159.
- 29
30 35. Collett D. *Modelling survival data in medical research*. London: Chapman & Hall; 1994.
- 31
32 36. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R.
33 Underestimation of risk associations due to regression dilution in long-term follow-up of
34 prospective studies. *Am J Epidemiol* 1999; **150**: 341-353.
- 35
36 37. Rosner B, Willett WC, Spiegelman D. Correction of logistic regression relative risk
37 estimates and confidence intervals for systematic within-person measurement error. *Stat*
38 *Med* 1989; **8**: 1051-1069.
- 39
40 38. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk
41 estimates and confidence intervals for measurement error: the case of multiple covariates
42 measured with error. *Am J Epidemiol* 1990; **132**: 734-745.
- 43
44 39. Fibrinogen Studies Collaboration. Regression dilution methods for meta-analysis: assessing
45 long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. *Int J*
46 *Epidemiol* 2006; **35**: 1570-1578.
- 47
48 40. Fibrinogen Studies Collaboration. Correcting for multivariate measurement error by regression
49 calibration in meta-analyses of epidemiological studies. *Stat Med* 2009; **28**: 1067-1092.
- 50
51
52
53
54
55
56
57
58
59
60

- 1
- 2
- 3
- 4
- 5 41. Breslow NE, Day NE. *Statistical methods in cancer research. Volume 1: The analysis of*
- 6 *case-control studies*. Lyon: IARC Scientific Publications, 1980.
- 7
- 8 42. Rodrigues L, Kirkwood BR. Case-control designs in the study of common diseases: updates
- 9 on the demise of the rare disease assumption and the choice of sampling scheme for controls.
- 10 *Int J Epidemiol* 1990; **19**: 205-213.
- 11
- 12 43. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention
- 13 trials. *Biometrika* 1986; **73**: 1-11.
- 14
- 15 44. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. *J Clin*
- 16 *Epidemiol* 1999; **52**: 1165-1172.
- 17
- 18 45. Stata: data analysis and statistical software, www.stata.com. StataCorp, Texas USA, 2009.
- 19
- 20 46. Simmonds MC, Higgins JPT, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-
- 21 analysis of individual patient data from randomised trials: a review of methods used in
- 22 practice. *Clin Trials* 2005; **2**: 209-17.
- 23
- 24 47. Pooling Project of Prospective Studies of Diet and Cancer (Smith-Warner SA *et al*) .
- 25 Methods for pooling results of epidemiologic studies. *Am J Epidemiol* 2006; **163**: 1053-1064.
- 26
- 27 48. Bennett DA. Review of analytical methods for prospective cohort studies using time to event
- 28 data: single studies and implications for meta-analysis. *Stat Methods Med Res* 2003; **12**:
- 29 297-319.
- 30
- 31 49. Fibrinogen Studies Collaboration. Systematically missing confounders in individual participant
- 32 data meta-analysis of observational cohort studies. *Stat Med* 2009; **28**: 1218-1237.
- 33
- 34 50. Carroll RJ, Stefanski LA. Measurement error, instrumental variables and corrections for
- 35 attenuation with applications to meta-analyses. *Stat Med* 1994; **13**: 1265-1282.
- 36
- 37 51. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing
- 38 models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*
- 39 1996; **15**: 361-387.
- 40
- 41 52. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction.
- 42 *Circulation* 2007; **115**: 928-935.
- 43
- 44 53. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added
- 45 predictive ability of a new marker: from area under the ROC curve to reclassification and
- 46 beyond. *Stat Med* 2008; **27**: 157-172; discussion 207-212.
- 47
- 48 54. Fibrinogen Studies Collaboration. Measures to assess the prognostic ability of the stratified
- 49 Cox proportional hazards model. *Stat Med* 2009; **28**: 389-411.
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
55. Asia Pacific Cohort Studies Collaboration. Determinants of cardiovascular disease in the Asia Pacific region: protocol for a collaborative overview of cohort studies. *CVD Prevention* 1999; **2**: 281-289.
 56. Breast Cancer Linkage Consortium (Thompson D, Easton DF). Cancer Incidence in BRCA1 mutation carriers. *J Natl Cancer Inst* 2002; **94**: 1358-1365.
 57. Collaborative Group on Hormonal Factors in Breast Cancer (Beral V, Bull D, Doll R, Peto R, Reeves G). Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. *Lancet* 2004; **363**: 1007-1016.
 58. Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, Langdahl BL *et al*. The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. *Ann Intern Med* 2006; **145**: 255-264.
 59. Bingham S, Riboli E. Diet and cancer--the European Prospective Investigation into Cancer and Nutrition. *Nat Rev Cancer* 2004; **4**: 206-215.
 60. UK Biobank. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. *Int J Epidemiol* 2008; **37**: 234-244.
 61. UK Biobank protocol. Accessed at www.ukbiobank.ac.uk on 31 May 2009.
 62. Knoppers BM, Fortier I, Legault D, Burton P. The Public Population Project in Genomics (P3G): a proof of concept? *Eur J Hum Genet* 2008; **16**: 664-665.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1

Combined hazard ratios for the relationship between baseline fibrinogen (g/L) and CHD risk, adjusted for a linear effect of age at baseline in each study separately.

Method	Hazard ratio (95% CI)	Log hazard ratio $\hat{\beta}$ (SE)	Heterogeneity		
			Between-study variance $\hat{\tau}^2$	p-value	I^2 (95% CI)
Untransformed fibrinogen: Log hazard ratios per 1g/L increase					
Random-effects meta-analysis	1.57 (1.47 to 1.67)	0.450 (0.033)	0.018	<0.0001	64% (48, 76)
Fixed-effects meta-analysis	1.52 (1.47 to 1.57)	0.419 (0.018)	NA	<0.0001	NA
Transformed fibrinogen: Log hazard ratios per SD increase Random-effects meta-analysis					
Untransformed fibrinogen	1.34 (1.29 to 1.40)	0.294 (0.022)	0.008	<0.0001	64% (48, 76)
Log fibrinogen	1.38 (1.32 to 1.45)	0.325 (0.025)	0.010	<0.0001	65% (48, 76)
Study-specific SD score fibrinogen	1.34 (1.29 to 1.40)	0.292 (0.021)	0.007	<0.0001	63% (45, 75)
Study-specific SD score log fibrinogen	1.37 (1.31 to 1.44)	0.316 (0.024)	0.009	<0.0001	64% (47, 76)
Untransformed fibrinogen:					
Quadratic term for fibrinogen	0.96 (0.91 to 1.01)	-0.045 (0.027)	0.007	0.013	40% (7, 61)

NA not applicable

Table 2

Combined hazard ratios for CHD per 1g/L increase in baseline fibrinogen: random-effects meta-analysis adjusting for baseline confounding variables.

With adjustment for	Hazard ratio (95% CI)	Log hazard ratio $\hat{\beta}$ (SE)	χ_1^2	Heterogeneity		
				Between-study variance $\hat{\tau}^2$	p-value	I^2 (95% CI)
age	1.57 (1.47 to 1.67)	0.450 (0.033)	181	0.018	<0.0001	64% (48, 76)
age as 5-year age bands	1.57 (1.47 to 1.68)	0.451 (0.033)	183	0.018	<0.0001	64% (48, 76)
stratification by 5-year age bands	1.57 (1.47 to 1.68)	0.451 (0.033)	182	0.018	<0.0001	64% (48, 76)
age sex*age	1.57 (1.47 to 1.68)	0.450 (0.034)	180	0.018	<0.0001	65% (48, 76)
age age ²	1.56 (1.46 to 1.67)	0.447 (0.033)	179	0.018	<0.0001	64% (48, 76)
age age ² sex*age sex*age ²	1.57 (1.47 to 1.67)	0.448 (0.034)	177	0.019	<0.0001	65% (49, 76)
age smoking tchol sbp bmi [†]	1.38 (1.31 to 1.45)	0.320 (0.026)	156	0.006	0.028	35% (0, 58)

[†] smoking coded as current vs. other; tchol = total cholesterol; sbp = systolic blood pressure; bmi = body mass index

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3

Interactions between baseline fibrinogen (g/L) and potential effect modifiers for risk of CHD: differences in log hazard ratios adjusted for the main effects of baseline age, smoking, total cholesterol, systolic blood pressure and body mass index.

<i>Potential effect modifier</i>	<i>Estimated interaction between the potential effect modifier and fibrinogen</i>				
	<i>Number of cohorts</i>	<i>Number of subjects</i>	<i>Estimate δ (SE)</i>	<i>p-value</i>	<i>Heterogeneity I^2 (95% CI)</i>
Age (10 years)	31	154211	-0.095 (0.029)	0.001	0% (0, 40)
Systolic blood pressure (10 mmHg)	31	154211	-0.021 (0.010)	0.032	21% (0, 50)
Body mass index (5 kg/m ²)	31	154211	-0.079 (0.023)	<0.0001	3% (0, 31)
Total cholesterol (1 mmol/L)	31	154211	-0.025 (0.014)	0.081	1% (0, 41)
Sex: women vs. men					
Between-study interaction	31	154211	0.120 (0.092)	0.21	NA
Within-study interaction	16	90529	0.089 (0.061)	0.15	0% (0, 52)
Overall pooled interaction [†]	31	154211	0.098 (0.051)	0.054	NA

NA not applicable

[†] Meta-analysis of between-study and within-study interactions

Table 4

Non-proportional hazards (PH) for CHD risk assessed by the interaction of baseline fibrinogen (g/L) and time (years). The models include adjustment for age at baseline as a linear term.

<i>Method</i>	<i>Estimated non-PH parameter</i> ξ (SE)	χ^2 test		<i>Heterogeneity</i> I^2 (95% CI)
		χ^2 (df)	<i>p-value</i>	
Summed χ_1^2 statistics of non-PH parameter from each study	NA	24 (31)	0.80	NA
Summed χ_1^2 statistics from tests of Schoenfeld residuals in each study	NA	21 (31)	0.90	NA
Random-effects meta-analysis of study-specific non-PH parameters	0.0016 (0.0045)	0.12 (1)	0.73	0% (0, 40)

NA not applicable

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49


Table 5

Combined hazard ratios for CHD per 1g/L increase in fibrinogen, corrected for measurement error. All analyses are adjusted for age at baseline, sex, smoking, total cholesterol, systolic blood pressure and body mass index.

<i>Measurement error correction</i>	<i>Hazard ratio (95% CI)</i>	<i>Log hazard ratio (SE)</i>
No measurement error correction	1.38 (1.31 to 1.45)	0.320 (0.026)
Measurement error in fibrinogen	1.96 (1.76 to 2.17)	0.672 (0.053)
Measurement error in fibrinogen, smoking, total cholesterol, systolic BP, and body mass index	1.85 (1.66 to 2.06)	0.617 (0.055)

Figure 1

Study-specific hazard ratios and 95% confidence intervals (log scale) for the relationship of baseline fibrinogen with CHD in 31 studies, and meta-analysis. A 95% prediction interval for the true hazard ratio in a new study is also shown. Results are adjusted for age at baseline as a linear term. For acronyms to studies, see reference 10.



RE Random effects; FE fixed effects; NA not applicable

Figure 2

Combined log hazard ratios with 95% CIs based on floating absolute risks for the relationship between baseline fibrinogen (g/L) and CHD risk, plotted against mean baseline fibrinogen in fifths. From multivariate random-effects meta-analysis, adjusted for a linear effect of age at baseline in each study separately.




Figure 3

Interaction of baseline fibrinogen and age, derived from a proportional hazards model with time-dependent effect of age in each study, and combined using multivariate random-effects meta-analysis. Log hazard ratios with 95% CIs based on floating absolute risks, plotted against mean baseline fibrinogen in fifths.

